News

News

September 6, 2018

Presentation of Follicum at LSX Nordic Congress 30 August 2018

Follicum’s CEO Jan Alenfall presented the company at LSX Nordic Congress in Stockholm 30 August 2018. See the presentation For further information, please contact: Jan Alenfall – CEO, Follicum AB Telephone: +46 (0)46 – 19 21 97 Email: info@follicum.com About Follicum AB Follicum is a biotech company focused on the discovery and development of peptide-based […]

September 3, 2018

Interview with Jonas Edelswärd, new Member of the Board in Follicum

What is your background and what have you done before joining Follicum? I have more than 25 years of experience from various positions in high-tech start-up companies, particularly from the innovation environments around Lund University and Malmö University, Ideon Innovation and MINC incubator. I have also worked with more mature companies, such as CEO for […]

August 20, 2018

Interview with Alejandra Mørk, new Member of the Board in Follicum

What is your background and what have you done before joining Follicum? I have worked with drug development in Pharma for 18 years, in areas of clinical development, regulatory affairs, project management and was my last years in pharma overall responsible for Drug Development in Nycomed. During that period, I was also very engaged in […]

June 26, 2018

Summer Greetings from Follicum

The first part of 2018 has been a period of intensive development for Follicum. Reaching several milestones, we included the first patients in the new Phase II study for stimulation of hair growth, while simultaneously working to generate new preclinical data to strengthen the diabetes patent where we also included a new peptide class. Patient recruitment in the hair study has exceeded expectations and all patients were included in early June, meaning the project is running according to plan. Patients are treated thrice weekly for three months, which means that we plan to report the results during the last quarter of this year. We have also been busy developing and evaluating three different types of formulations of FOL-005 for application to the skin. Recently, we have announced that we chose a formulation that matches the requirements for stability and transport of FOL-005 to the hair follicle. Additionally, this formulation has the most appealing cosmetic properties.

June 20, 2018

Interview with Gun-Britt Fransson, new Chairman of the Board in Follicum

What is your background and what have you done before joining Follicum? I have a biomedical education with a PhD in Nutrition and have as long as I can remember been convinced that new research can make the world a better place. This has been reflected in my over 30-year career in research-leading positions in […]

May 16, 2018

Follicum will present FOL-005 at the scientific conference European Hair Research Society, 18-20 May 2018

Follicum AB (“Follicum” or “the Company”) today announces that CEO Jan Alenfall will give a presentation of the development of FOL-005 at the conference European Hair Research Society, which takes place in Bologna, Italy, 18-20 May 2018. The presentation will be included in the part of the conference that will discuss cell-based, growth-factor-based and pharmaceutical […]

May 7, 2018

Abstract accepted for poster presentation at the International Investigative Dermatology Conference in Orlando, May 16-19 2018

Follicum AB (“Follicum” or “the Company”) a clinical stage company focused on developing a novel peptide to promote hair growth, today, May 7, announces that an abstract has been accepted for poster presentation during the International Investigative Dermatology Conference to be held in Orlando, USA May 16-19 2018.The abstract will be presented by Follicum´s partner, […]

February 6, 2018

Interview with CEO Jan Alenfall

The interview made by Aktiespararna (in English) with Follicum’s CEO Jan Alenfall is now published on our webpage: http://follicum.com/investors/presentations/

February 1, 2018

Welcome to our new website!

Our new webpage, www.follicum.com, will make it much easier to access information about our two, main therapy areas, hair growth and diabetes. The starting page will be the English version, as we need to reach an international audience. – The website makes it smoother and easier to navigate for all stakeholders, says Jan Alenfall, CEO […]